Globotriaosylsphingosine accumulation and not alpha-galactosidase-a deficiency causes endothelial dysfunction in fabry disease

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Namdar, Mehdi ^a,b   Gebhard, Catherine ^b,c   Studiger, Rafael ^c   Shi, Yi ^c   Mocharla, Pavani ^c   Schmied, Christian ^b   Brugada, Pedro ^a   Lüscher, Thomas F ^b,c   Camici, Giovanni G ^c  

^a Heart Rhythm Management Centre UZB   (Belgium)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLOBOTRIAOSYLSPHINGOSINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; SMALL INTERFERING RNA; SPHINGOLIPID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; GLYCOLIPID;

ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME DEFICIENCY; FABRY DISEASE; GENE SILENCING; HEART MUSCLE CELL; HUMAN; HUMAN CELL; INCUBATION TIME; MACROVASCULAR ENDOTHELIAL CELL; MICROVASCULAR ENDOTHELIAL CELL; PROTEIN EXPRESSION; RNA INTERFERENCE; CORONARY BLOOD VESSEL; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROVASCULATURE; PATHOLOGY; VASCULAR ENDOTHELIUM;

ALPHA-GALACTOSIDASE; CORONARY VESSELS; CYCLOOXYGENASE 2; ENDOTHELIUM, VASCULAR; FABRY DISEASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE SILENCING; GLYCOLIPIDS; HUMANS; MICROVESSELS; SPHINGOLIPIDS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84860425284     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036373     Document Type: Article

References (38)

1. Zarate YA, Hopkin RJ, (2008) Fabry's disease. Lancet 372: 1427-1435.
2. Park JL, Whitesall SE, D'Alecy LG, Shu L, Shayman JA, (2008) Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin Exp Pharmacol Physiol 35: 1156-1163.
3. Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, et al. (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92: 357-360.
4. Kalliokoski RJ, Kalliokoski KK, Sundell J, Engblom E, Penttinen M, et al. (2005) Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis 28: 563-573.
5. Wang RY, Lelis A, Mirocha J, Wilcox WR, (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9: 34-45.
6. Eitzman DT, Bodary PF, Shen Y, Khairallah CG, Wild SR, et al. (2003) Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol 14: 298-302.
7. Gebhard C, Akhmedov A, Mocharla P, Angstenberger J, Sahbai S, et al. (2010) PDGF-CC induces tissue factor expression: role of PDGF receptor alpha/beta. Basic Res Cardiol 105: 349-356.
8. Camici GG, Schiavoni M, Francia P, Bachschmid M, Martin-Padura I, et al. (2007) Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci U S A 104: 5217-5222.
9. Thomaidis T, Relle M, Golbas M, Brochhausen C, Galle PR, et al. (2009) Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy. Kidney Int 75: 399-407.
10. Kanda A, Nakao S, Tsuyama S, Murata F, Kanzaki T, (2000) Fabry disease: ultrastructural lectin histochemical analyses of lysosomal deposits. Virchows Arch 436: 36-42.
11. Askari H, Kaneski CR, Semino-Mora C, Desai P, Ang A, et al. (2007) Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch 451: 823-834.
12. Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, et al. (2001) Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 32: 1559-1562.
13. Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, et al. (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104: 1506-1512.
14. Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, et al. (2005) Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111: 629-632.
15. Shu L, Park JL, Byun J, Pennathur S, Kollmeyer J, et al. (2009) Decreased nitric oxide bioavailability in a mouse model of Fabry disease. J Am Soc Nephrol 20: 1975-1985.
16. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL, (2001) Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 103: 3099-3104.
17. Tang EH, Ku DD, Tipoe GL, Feletou M, Man RY, et al. (2005) Endothelium-dependent contractions occur in the aorta of wild-type and COX2-/- knockout but not COX1-/- knockout mice. J Cardiovasc Pharmacol 46: 761-765.
18. Vanhoutte PM, Feletou M, Taddei S, (2005) Endothelium-dependent contractions in hypertension. Br J Pharmacol 144: 449-458.
19. Park JL, Shu L, Shayman JA, (2009) Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse. Am J Physiol Heart Circ Physiol 296: H1133-1140.
20. Bulut D, Liaghat S, Hanefeld C, Koll R, Miebach T, et al. (2003) Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J Hypertens 21: 1663-1667.
21. Szerafin T, Erdei N, Fulop T, Pasztor ET, Edes I, et al. (2006) Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus. Circ Res 99: e12-17.
22. Andersohn F, Suissa S, Garbe E, (2006) Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 113: 1950-1957.
23. Tang EH, Leung FP, Huang Y, Feletou M, So KF, et al. (2007) Calcium and reactive oxygen species increase in endothelial cells in response to releasers of endothelium-derived contracting factor. Br J Pharmacol 151: 15-23.
24. Yang D, Feletou M, Boulanger CM, Wu HF, Levens N, et al. (2002) Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br J Pharmacol 136: 104-110.
25. Merat S, Fruebis J, Sutphin M, Silvestre M, Reaven PD, (2000) Effect of aging on aortic expression of the vascular cell adhesion molecule-1 and atherosclerosis in murine models of atherosclerosis. J Gerontol A Biol Sci Med Sci 55: B85-94.
26. Hartford M, Wiklund O, Mattsson Hulten L, Persson A, Karlsson T, et al. (2007) C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. J Intern Med 262: 526-536.
27. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutiere B, et al. (2000) Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 47: 229-233.
28. Demuth K, Germain DP, (2002) Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr (Suppl 91): 57-61.
29. Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, et al. (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 95: 163-168.
30. Mitsias P, Levine SR, (1996) Cerebrovascular complications of Fabry's disease. Ann Neurol 40: 8-17.
31. Crutchfield KE, Patronas NJ, Dambrosia JM, Frei KP, Banerjee TK, et al. (1998) Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50: 1746-1749.
32. Grewal RP, (1994) Stroke in Fabry's disease. J Neurol 241: 153-156.
33. Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, et al. (2010) Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab 99: 99-108.
34. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, et al. (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138: 338-346.
35. Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, et al. (2006) Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 26: 839-844.
36. Ries M, Clarke JT, Whybra C, Mehta A, Loveday KS, et al. (2007) Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents. J Clin Pharmacol 47: 1222-1230.
37. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, et al. (2001) Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345: 9-16.
38. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, et al. (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105: 2812-2817.